Mesenchymal stem cell therapy for liver fibrosis
The Korean Journal of Internal Medicine
;
: 580-589, 2015.
Artigo
em Inglês
| WPRIM
| ID: wpr-216634
ABSTRACT
Currently, the most effective treatment for end-stage liver fibrosis is liver transplantation; however, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical costs. Recently, mesenchymal stem cell (MSC) therapy has been suggested as an effective alternate approach for the treatment of hepatic diseases. MSCs have the potential to differentiate into hepatocytes, and therapeutic value exists in their immune-modulatory properties and secretion of trophic factors, such as growth factors and cytokines. In addition, MSCs can suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, regress liver fibrosis and enhance liver functionality. Despite these advantages, issues remain; MSCs also have fibrogenic potential and the capacity to promote tumor cell growth and oncogenicity. This paper summarizes the properties of MSCs for regenerative medicine and their therapeutic mechanisms and clinical application in the treatment of liver fibrosis. We also present several outstanding risks, including their fibrogenic potential and their capacity to promote pre-existing tumor cell growth and oncogenicity.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fenótipo
/
Transdução de Sinais
/
Diferenciação Celular
/
Fatores de Risco
/
Resultado do Tratamento
/
Hepatócitos
/
Transplante de Células-Tronco Mesenquimais
/
Medicina Regenerativa
/
Proliferação de Células
/
Células-Tronco Mesenquimais
Tipo de estudo:
Estudo de etiologia
/
Fatores de risco
Limite:
Animais
/
Humanos
Idioma:
Inglês
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS